Lucira Health to Participate in LifeSci Partners HealthTech Symposium
Lucira Health, a medical technology company, announced its participation in the LifeSci Partners HealthTech Symposium on September 21, 2022, at 10:30 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lucira Health, a medical technology company, announced its participation in the LifeSci Partners HealthTech Symposium on September 21, 2022, at 10:30 AM ET. The event will showcase Lucira's innovative infectious disease test kits and its digital health platform aimed at connecting patients with providers. The company has made lab-quality diagnostics more accessible with its PCR-quality test results, expanding its offerings beyond COVID-19 to include tests for respiratory infections, women's health, and STIs. A live webcast will be available on Lucira's website.
Details
News Market Reaction – LHDX
The recorded move for LHDX in the trading session of this news was +4.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, and a digital health platform that will connect patients with providers, today announced that the company will participate in the LifeSci Partners HealthTech Symposium on September 21st, 2022, at 10:30am ET. A live and archived webcast of the event can be accessed through the Events and Presentations page of the Lucira website.
About Lucira Health
Lucira is a medical technology company focused on the development and commercialization of innovative infectious disease tests to make lab-quality diagnostics more accessible. Lucira designed its test platform to provide accurate, reliable, PCR-quality test results anywhere and at any time. Beyond its already commercialized COVID-19 and COVID-19 & Flu Tests, Lucira is working on new diagnostic tests for respiratory infections and other categories including women’s health and sexually transmitted infections (STIs). For more information, visit www.lucirahealth.com.
Investor Contact
Greg Chodaczek
Investorrelations@lucirahealth.com
332-895-3230
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.